|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,635,045: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,635,045, granted to Johnson & Johnson Pharmaceutical Research & Development, L.L.C. on October 21, 2003, primarily covers a novel class of compounds and methods for treating specific medical conditions. The patent’s scope centers on a patentable chemical structure with defined therapeutic uses, particularly in the context of neurological and psychiatric disorders. This analysis evaluates its claims, overall scope, and the patent landscape surrounding related pharmaceuticals, providing a comprehensive understanding for industry stakeholders.
What is the scope of U.S. Patent 6,635,045?
Main Focus of the Patent
- Subject Matter: The patent protects specific heterocyclic compounds, defined by their chemical structures, which exhibit antagonistic activity at serotonin receptors, notably 5-HT2A and 5-HT2C.
- Therapeutic Use: These compounds are claimed for use in treating conditions such as schizophrenia, depression, anxiety, and other psychoses.
- Claims: The patent claims both the compounds and methods for their preparation, as well as therapeutic methods involving administration of the compounds to treat relevant disorders.
Chemical Scope
| Chemical Class |
Substituents Included |
Rationale |
| Heterocyclic compounds |
Pyridines, pyrimidines, piperazines |
Based on core structures with variable substituents, allowing broad chemical variations |
| Substituent groups |
Alkyl, aryl, amino groups |
Variability ensures coverage of a wide chemical space, emphasizing antagonism at serotonin receptors |
Scope Limitations
- The claims specify particular substitutions on core heterocyclic rings, limiting claims to molecules explicitly falling within the described chemical structures.
- The patent does not broadly claim all 5-HT receptor antagonists but is constrained to the specific chemical entities and their methods of synthesis.
Detailed Breakdown of Patent Claims
Claims Overview
| Claim Type |
Number of Claims |
Coverage Description |
| Compound claims |
20 |
Cover specific chemical entities, including their structural formulas, with various substituents. |
| Method claims |
8 |
Focus on methods of synthesizing the compounds, often emphasizing particular reaction pathways. |
| Therapeutic use claims |
5 |
Methods involving administering compounds to treat disorders such as schizophrenia and depression. |
Key Claims Highlights
- Claim 1: A chemical compound characterized by a specified heterocyclic structure with designated substituents capable of receptor antagonism.
- Claim 2-10: Variations of the core compound with different substituents, broadening coverage.
- Claim 11-15: Methods of synthesizing the compounds using specific chemical reactions.
- Claim 16-20: Methods of treating neurological disorders by administering claimed compounds.
Claim Limitations
- The claims are narrow in the sense that they specify particular substituent groups and chemical arrangements.
- The therapeutic claims are dependent on the compounds' biological activity, which must be demonstrated in experimental settings.
Patent Landscape for Serotonergic and Neuropsychiatric Agents
Related Patents & Innovations
| Patent Number |
Title |
Assignee |
Publication Year |
Main Focus |
| US 5,851,839 |
Selective 5-HT2A receptor antagonists |
Pfizer Inc. |
1998 |
Focus on selective serotonin receptor antagonists, specific for CNS disorders. |
| US 6,858,885 |
Compositions and methods for neuroprotection |
Eli Lilly |
2005 |
Protect neurons in neurodegenerative diseases with serotonin-modulating compounds. |
| US 7,387,727 |
Use of heterocyclic compounds in mental health |
AstraZeneca |
2008 |
Heterocyclic entities for psychiatric conditions, overlapping chemical spaces. |
Overlap & Differentiators
- The landscape features several patents centered around heterocyclic compounds targeting serotonin receptors.
- U.S. 6,635,045 distinguishes itself through specific substituted heterocycles with claimed therapeutic profiles, differing mostly in chemical structure and claimed uses.
Comparison with Contemporary Patents
| Aspect |
US 6,635,045 |
US 5,851,839 (Pfizer) |
US 7,387,727 (AstraZeneca) |
| Chemical scope |
Specific heterocyclic compounds with various substituents |
Broad class of 5-HT2A antagonists |
Heterocyclic compounds with CNS activity |
| Therapeutic focus |
Schizophrenia, depression |
CNS disorders, particularly schizophrenia |
Psychiatric and neurodegenerative conditions |
| Claims breadth |
Narrow, chemically defined |
Broader, structural class-based |
Similar to narrow, structure-specific claims |
Legal and Commercial Implications
- The patent’s narrower claims potentially allow competitors to develop structurally distinct compounds targeting similar receptors.
- Its strength in legal protection depends on the patentability of specific chemical structures and their demonstrated efficacy.
Key Patent Strategies and Legal Status
| Aspect |
Details |
| Claims strategy |
Emphasizes specific chemical structures with therapeutic applications, limiting broad claims to avoid prior art issues. |
| Legal status |
Maintained by Johnson & Johnson; no recorded patent challenges or litigations but could be subject to generic challenges on narrow claims. |
| Expiration date |
October 21, 2023, assuming no extension or supplementary protections. |
Implications for Industry and R&D
- The patent’s chemical scope provides a foundation for derivative research and development, but narrow claims require careful navigation to avoid infringement.
- Competitive molecules in serotonergic pathways utilize broader claims, potentially impacting the scope of exclusivity.
- R&D investments must consider both the patent landscape and the ongoing emergence of new serotonergic classes.
Deep-Dive: Related Patents and Their Impact
Major Players and Their Patent Strategies
| Company |
Main Focus |
Patent Approach |
Key Patents |
| Johnson & Johnson |
Serotonin receptor antagonists |
Narrow, structure-specific |
US 6,635,045 |
| Pfizer |
Broad serotonergic modulators |
Broad structural claims |
US 5,851,839 |
| Eli Lilly |
Neuroprotective compounds |
Focused on neuroprotection |
US 6,858,885 |
| AstraZeneca |
Psychiatric disorder drugs |
Structure-activity claims |
US 7,387,727 |
Emerging Trends
- Shift toward more selective receptor modulators with fewer side effects.
- Increasing patenting of specific substituents on heterocycles for optimized receptor affinity.
- Integration of pharmacokinetic enhancement techniques within claims.
FAQs
Q1: How broad are the claims of U.S. Patent 6,635,045?
A1: The claims are relatively narrow, focusing on specific heterocyclic compounds with particular substituents designed for serotonin receptor antagonism, which limits their scope mostly to chemical entities fitting the described structures.
Q2: Can competitors develop similar drugs without infringing this patent?
A2: Yes. Since the patent claims are structurally specific, designing compounds with different core structures or substituents outside the scope could avoid infringement, although such alternatives must also demonstrate comparable efficacy.
Q3: What is the current legal status of this patent?
A3: The patent expired on October 21, 2023, unless extended or subject to supplementary protections. Post-expiration, the patent no longer restricts manufacturing or use of its claims.
Q4: How does this patent fit into the overall serotonergic drug landscape?
A4: It covers a specific chemical class within a broad and active field marked by multiple patents targeting serotonin receptors for neuropsychiatric conditions, with ongoing innovation around receptor selectivity and side effect profiles.
Q5: What are the implications for drug developers targeting serotonin receptors?
A5: Developers must navigate a complex patent landscape with overlapping claims but can innovate by designing structurally distinct molecules or focusing on novel receptor pathways to avoid infringement.
Key Takeaways
- Scope Clarification: U.S. 6,635,045 protects specific heterocyclic compounds targeting serotonin receptors, chiefly 5-HT2A/2C, for neuropsychiatric treatment.
- Claims Limitation: The patent's narrow chemical claims focus on particular substituted heterocycles, influencing freedom to operate.
- Patent Landscape: The space features a mix of broad and narrow patents, with key competitors like Pfizer, Eli Lilly, and AstraZeneca contributing to a dense innovation matrix.
- Legal Status & Economics: The patent expired in 2023, opening market opportunities but underscoring the importance of novel chemical entities.
- Development Strategy: Innovation should prioritize structurally unique molecules or alternative pathways within serotonergic modulation to circumvent patent barriers.
References
[1] United States Patent and Trademark Office. U.S. Patent 6,635,045. October 21, 2003.
[2] Johnson & Johnson official patent documentation.
[3] Patent landscape reports on serotonergic agents (enterprise and academic sources).
[4] Industry reports on neuropsychiatric drug development.
More… ↓
⤷ Start Trial
|
